Physician profile
Susan E Stinehelfer
NPI 1194926832
$2,936.32
in general payments reported to CMS, 2019-2025
30 companies · $417 in 2025
The $417 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482 · 2020: $289 · 2021: $96.78 · 2022: $414 · 2023: $604 · 2024: $634 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,387 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,386.79 |
| Education | $268.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $557.36 | 2019-2025 | Skyrizi |
| Janssen Biotech, INC. | $417.00 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $294.29 | 2019-2025 | Winlevi, Blu-U, Odomzo |
| Leo Pharma INC. | $255.64 | 2019-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $181.63 | 2022-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $153.27 | 2019-2025 | |
| Pfizer INC. | $123.51 | 2019-2025 | |
| Ucb, INC. | $120.26 | 2023-2025 | Bimzelx, Cimzia |
| Amgen INC. | $84.47 | 2020-2024 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $82.19 | 2022-2025 | Sotyktu |
| Incyte Corporation | $73.15 | 2022-2024 | Opzelura |
| Dermavant Sciences, INC. | $66.97 | 2023-2024 | Vtama |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $66.10 | 2019 | |
| Arcutis Biotherapeutics, INC. | $64.97 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $56.94 | 2019-2025 | Jublia, Cabtreo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $41.65 | 2023-2024 | |
| Genzyme Corporation | $36.88 | 2019-2020 | |
| Biofrontera INC. | $36.71 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Lilly USA, LLC | $32.01 | 2019-2022 | |
| Allergan, INC. | $22.99 | 2019 | |
| Verrica Pharmaceuticals INC. | $22.59 | 2024 | Ycanth |
| Journey Medical Corporation | $21.00 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.76 | 2023 | Spevigo |
| Aclaris Therapeutics, INC. | $17.47 | 2019 | |
| Dermira, INC. | $16.75 | 2019 | |
| Fresenius Kabi USA, LLC | $16.40 | 2023 | Idacio |
| Kyowa Kirin, INC. | $15.60 | 2023 | Poteligeo |
| Almirall LLC | $13.69 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $12.87 | 2019 | |
| Mayne Pharma Commercial LLC | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Stinehelfer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.